Buscar
Mostrando ítems 1-4 de 4
Artículo
Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
(Elsevier Science BV, 2022)
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), ...
Artículo
Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia
(ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022)
Despite being a major cause of disability worldwide, the pathophysiology of schizophrenia and molecular basis of treatment response heterogeneity continue to be unresolved. Recent evidence suggests that multiple aspects ...
Artículo
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
(Oxford University Press, 2020)
Background: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to ...
Artículo
Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program
(Elsevier, 2020)
This article describes data related to the research study entitled "Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study." [1]. We present data concerning ...